Stockwinners Market Radar for February 14, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:00 EST Arcturus Therapeutics says Hughes steps down as Chief Medical Officer - In a regulatory filing after the close on Friday, Arcturus Therapeutics disclosed that effective February 14, Dr. Steve Hughes will step down from his position as Chief Medical Officer of the company and will "continue to support the company and its programs for the immediate future in the role of Strategic Clinical Advisor." Dr. Kelly Lindert, the company's Senior Vice President and Head of Vaccines, will take on the role of Chief Development Officer, Vaccines, for the company, Arcturus noted.

18:19 EST Otter Tail increases quarterly dividend 5.8% to 41.25c per share - Otter Tail increased the quarterly common stock dividend to 41.25c per share, an indicated annual dividend rate of $1.65 per share and a 5.8% increase from $1.56 per share in 2021.

18:08 EST Arvinas reports new, positive data on bavdegalutamide - Arvinas announced the presentation of new data showing that bavdegalutamide, a novel PROTAC protein degrader targeting the androgen receptor, continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant prostate cancer. These data show that bavdegalutamide reduced prostate-specific antigen levels greater than or equal to 50% in 46% of patients with tumors harboring AR T878X/H875Y mutations. Updated Phase 1 and interim Phase 2 ARDENT data will be presented in both a rapid abstract session and a poster session on February 17, at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium. "These results are very encouraging and reinforce our conviction that bavdegalutamide has the potential to provide meaningful clinical benefit to patients with mCRPC who have progressed after treatment with novel hormonal agents and for whom few treatment options exist," said John Houston, Ph.D., president and CEO of Arvinas. "With particularly robust activity in a molecularly defined patient population, we believe there is a clear path forward to developing this novel treatment as a precision medicine and plan to initiate a pivotal trial by year end 2022."

18:01 EST Whirlpool raises quarterly dividend 25%, raises share repurchase plan by $2B - The board of directors of Whirlpool authorized an additional $2B in share repurchases under the company's ongoing share repurchase program. Approximately $1.5B remained available under the program as of December 31, 2021. The company's board of directors also approved a 35c increase in the quarterly dividend on the company's common stock to $1.75 per share from $1.40 per share. The dividend is payable March 15 to stockholders of record at the close of business on February 25.

17:59 EST Governor Hochul announces start of building of NY's 1st offshore wind project - Governor Kathy Hochul alongside United States Secretary of the Interior Deb Haaland and other elected officials, celebrated the start of construction of South Fork Wind, New York's first offshore wind project, jointly developed by Orsted and Eversourceoff the coast of Long Island. "Building on the Bureau of Ocean Energy Management's (BOEM) January issuance of the Final Sale Notice for the New York Bight, the recent key offshore wind contract milestone, and the State of the State announcement of a nation-leading $500M investment in offshore wind ports, manufacturing, and supply chain infrastructure to accompany New York's next offshore wind solicitation, New York continues to advance the Climate Leadership and Community Protection Act goal to develop 9,000 megawatts of offshore wind by 2035. "The harsh impacts and costly realities of climate change are all too familiar on Long Island, but today as we break ground on New York's first offshore wind project we are delivering on the promise of a cleaner, greener path forward that will benefit generations to come," Governor Hochul said. "South Fork Wind will eliminate up to six million tons of carbon emissions over the next twenty-five years benefiting not only the Empire State, but our nation as a whole. This project will also create hundreds of good-paying jobs, helping spur economic growth across the region as we continue to recover from COVID-19. This is a historic day for New York, and I look forward to continue working with Secretary Haaland as we lead our nation toward a greener, brighter future for all." Companies in the offshore wind complex include: (APO) last year bought into offshore wind developer U.S. Wind, which is working on a federal lease area off the coast of Maryland," said Gov. NY State Kathy Hochul. Companies in the space include: Siemens (SIEGY), Apollo Global (APO), and General Electric (GE) l First Trust Global Wind Energy (WINDY) General Electric (GE), NextEra Energy (NEE) and Berkshire Hathaway (BRK.A, BRK.B). Reference Link

17:43 EST Volta announces collaboration expansion with Walgreens - Volta (VLTA) announced the expansion of its collaboration with Walgreens (WBA;WAG) to target installing 1,000 DC fast charging stalls at over 500 Walgreens throughout the U.S. Volta provides seamless, universal, and reliable EV charging - centered on consumer behavior - located where people live, shop, work, and play. With unique charging stations that connect clean miles to commerce, Volta's intelligent network is among the most utilized in the U.S. Volta began working with Walgreens (WAG) in 2019 and currently has stations across 49 of its stores. "As we expand our DC Fast charging presence across the country, Walgreens is an ideal match for faster forms of Volta charging given the average time a Walgreens shopper typically spends in-store," said Scott Mercer, Founder and CEO of Volta. "Volta's intelligent charging network is built around understanding and anticipating consumer behavior. The next phase of our work with Walgreens will provide people with a quick, convenient, and meaningful charge that is tailored to their shopping experience while bringing us another step closer to a clean energy future."

17:33 EST Third Point buys Rivian, exits Meta in Q4 - Third Point disclosed in an SEC filing its holdings as of December 31, 2021. The fund's 24 new buys during the fourth quarter included, by size of position, Accenture (ACN), Rivian (RIVN), Expedia (EXPE), Align Technology (ALGN), and Hertz Global (HTZ). Third Point exited 45 positions during the quarter, including by size of previous position Intel (INTC), Endeavor (EDR), Meta Platform (FB), Visa (V), and Paysafe (PSFE). The fund increased its stake in 17 holdings, including by size of previous position Amazon (AMZN), Intuit (INTU), UnitedHealth (UNH), RH (RH), and Danaher (DHR). Third Point reduced its stake in ten holdings, including by size of previous position Upstart (UPST), Disney (DIS), Alight (ALIT), TransDigm (TDG), and Aurora Innovation (AUR). The fund's top holdings as of December 31, in order of size, were Danaher, PG&E (PCG), Amazon, Intuit, Alphabet Class A (GOOGL).

17:27 EST Berkshire Hathaway announces resignation of Tom Murphy from board - Tom Murphy, a member of Berkshire Hathaway's Board of Directors since 2003, has resigned from Berkshire's Board effective February 14. Warren Buffett, Berkshire's Chairman and CEO, issued the following statement. "Tom Murphy has taught me more about running a business than any other person. We have been friends and mental partners for more than 50 years. My only regret is that I didn't meet him earlier. Tom phoned me today and said that recovering from a recent bout with Covid convinced him that he would feel more comfortable ending his activities at Berkshire. I accepted his wish. He will continue as a major shareholder and friend."

17:23 EST Pershing Square cuts stake in Hilton Worldwide - Bill Ackman's Pershing Square Capital Management disclosed in an SEC filing its holdings as of December 31, 2021. Pershing Square reduced its stake in Hilton Worldwide (HLT) by 2.3%. Pershing Square's top holdings as of December 31, 2021, in order of size, were Lowe's (LOW), Hilton Worldwide, Chipotle Mexican Grill (CMG), Restaurant Brands (QSR), and Howard Hughes (HHC).

17:18 EST ImmunityBio reports 'positive data' from late-stage bladder cancer trial - ImmunityBio announced positive data from the company's late-stage bladder cancer trial (QUILT-3.032). The data showed sustained complete response rates in patients with BCG-unresponsive non-muscle invasive carcinoma in situ bladder cancer (Cohort A) and with papillary disease (Cohort B). Of the 83 patients with BCG-unresponsive NMIBC CIS, 59 (71%) had a complete response with a median duration of response of 24.1 months-exceeding historical complete response rates of 41% and 18% for FDA-approved therapies pembrolizumab and valrubicin, respectively. In the papillary disease arm of the study (Cohort B), 57% of patients are disease free at 12 months and 53% at 18 months. "We are excited with these promising results," said Sam Chang, M.D., Urologic Surgery Chief Surgical Officer, Vanderbilt Ingram Cancer Center and trial investigator. "This study suggests that BCG induces trained immunity as the prime, while N-803 serves as a vital boost for innate immune memory. These results of high efficacy activity and excellent safety profile set a new bar for NMIBC treatment, and together with the familiar and favorable mode of administration, will advance our current standards of care for patients with bladder cancer."

17:17 EST Starboard Value adds GoDaddy, boosts Huntsman in Q4 - Jeffrey Smith's Starboard Value disclosed in an SEC filing its holdings as of December 31, 2021. The fund's 95 new buys during the fourth quarter included, by size of position, GoDaddy (GDDY), Willis Towers Watson (WLTW), Colfax (CFX), Onyx Acquisition I (ONYX), and McLaren Technology (MLAI). Starboard exited 25 holdings during the quarter, including by size of previous position Box (BOX), comScore (SCOR), Nextdoor (KIND), Fathom Digital Manufacturing (FATH), and Bird Global (BRDS). The fund increased its stake in six holdings, including by size of previous position Huntsman (HUN), Cerner (CERN), System1 (SST), Data Knights Acquisition Corp. Class A (DKDCA), and CommVault (CVLT). Starboard reduced its stake in 25 holdings, including by size of previous position Merit Medical (MMSI), iShares Russell 2000 ETF (IWM), MedTech Acquisition Corp. Class A (MTAC), Warburg Pincus Capital I B (WPCB), and Lead Edge Growth Opportunities Class A (LEGA). The fund's top holdings as of December 31, in order of size, were Huntsman, GoDaddy, Aecom (ACM), ON Semiconductor (ON), and Willis Towers Watson.

17:09 EST Lone Pine takes stakes in Mastercard, Visa, exits Twitter, Meta Platforms - Stephen Mandel's Lone Pine Capital disclosed in an SEC filing its holdings as of December 31, 2021. Lone Pine Capital's five new buys during the fourth quarter included, by size of position, Mastercard (MA), Visa (V), Snowflake (SNOW), Sweetgreen (SG), and AvidXchange (AVDX). Lone Pine Capital exited fifteen positions during the quarter, including by size of previous position, Twitter (TWTR), Moderna (MRNA), Meta Platforms (FB), Coupa Software (COUP), and Dexcom (DXCM). Lone Pine Capital increased its stake in twelve holdings, including by size of previous position, Amazon (AMZN), NetEase (NTES), Workday (WDAY), Confluent (CFLT), and Marqeta (MQ). Lone Pine Capital reduced its stake in eight holdings, including by size of previous position, Block (SQ), Adobe (ADBE), Datadog (DDOG), ServiceNow (NOW), and Shopify (SHOP). Lone Pine Capital's top holdings as of December 31, 2021, in order of size, were Amazon, Shopify, Mastercard, Bath & Body Works (BBWI) and Workday.

17:07 EST Murata to acquire Resonant for $4.50 per share in cash - Murata Electronics North America, Inc., a wholly owned subsidiary of Murata Manufacturing Co., Ltd., and Resonant Inc. announced that they have entered into a definitive agreement under which Murata will acquire all outstanding shares of Resonant not owned by Murata for $4.50 per share in cash. "This acquisition will combine Murata's world-leading mobile RF product capabilities with Resonant's best-in-class XBAR filter solutions and world-class team of talented engineers," said Norio Nakajima, President of Murata. "Resonant invented its proprietary XBAR technology, which is expected to achieve higher frequency and superior performance to other filter technologies. We have collaborated closely with Resonant for many years on the development of proprietary circuit designs using Resonant's XBAR technology, and Resonant licensed to Murata rights for products in multiple specific radio frequencies in connection with our commercial partnership. We are confident Resonant's innovation is a key strategic differentiator for the mobile industry. This transaction will deepen our existing partnership and position us to better meet our customers' needs and expand opportunities for Murata." The transaction, which has been approved by both companies' boards of directors, is expected to close by the end of March 2022, subject to the tender of a majority of Resonant's shares, certain regulatory approvals and other customary closing conditions.

17:05 EST Elliott buys Switch, exits Public Storage in Q4 - Paul Singer's Elliott Management disclosed in an SEC filing its holdings as of December 31, 2021. The fund's two new buys during the second quarter included, by size of position, Switch (SWCH). Elliott exited four positions during the quarter, including by size of previous position Public Storage (PSA), Frontier Communications (FYBR), and Ryanair (RYAAY). The fund increased its stake in two holdings, including Valaris (VAL). Elliott reduced its stake in five holdings, including by size of previous position Dell Technologies (DELL), Arconic (ARNC), Peabody Energy (BTU), E2open (ETWO), and Evergy (EVRG). The fund's top holdings as of December 31, in order of size, were Howmet Aerospace (HWM), Marathon Petroleum (MPC), Evergy, Dell Technologies, and Twitter (TWTR).

17:03 EST Resonant trading halted, news pending

17:03 EST Merck, AstraZeneca report 'positive' results from Phase 3 PROpel trial - AstraZeneca (AZN) and Merck (MRK) announced that positive results from the Phase 3 PROpel trial showed LYNPARZA in combination with abiraterone plus prednisone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival versus abiraterone plus prednisone, a standard of care, as a first-line treatment for patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.

16:52 EST Icahn boosts Xerox, cuts Delek in Q4 - Carl Icahn's Icahn Capital disclosed in an SEC filing its holdings as of December 31, 2021. The fund increased its position in four holdings during the fourth quarter, including by size of previous position Icahn Enterprises (IEP), Southwest Gas (SWX), Xerox (XRX), and Bausch Health (BHC). Icahn reduced its stake in three holdings, including by size of previous position Herc Holdings (HRI) and Delek US (DK). The fund's top holdings as of December 31, in order of size, were Icahn Enterprises, Cheniere Energy (LNG), Occidental (OXY), CVR Energy (CVI), and Bausch Health.

16:44 EST Huntsman raises quarterly dividend 13% to 21.25c per share - The dividend is payable on March 31 to stockholders of record as of March 15.

16:40 EST Nogin to go public through Software Acquisition III merger agreement - Nogin and Software Acquisition III (SWAG) announced that the two companies have entered into a definitive merger agreement. Upon closing of the transaction, the combined company will be named Nogin and is expected to remain listed on the Nasdaq under the new ticker symbol (NOGN). Nogin is a commerce-as-a-service, or CaaS, cloud-based headless enterprise e-commerce platform for brands and merchants. Companies leveraging CaaS deliver enterprise class e-commerce at scale without having to purchase, implement, manage, optimize, or support any of the underlying infrastructure. The combined company will have an estimated post-transaction enterprise value of $646M, assuming no redemptions by SWAG III public stockholders. Cash proceeds from the transaction will consist of up to $211M of cash held in SWAG III's trust account. The net proceeds from the transaction will be used as working capital to support continued growth and to fund the repayment of existing debt. Nogin shareholders will roll 96% of their existing equity holdings into the combined company and are expected to own approximately 67% of the combined company on a non-fully diluted basis immediately following the closing of the business combination, assuming no redemptions by SWAG III's public stockholders. The boards of directors of each of SWAG III and Nogin approved the transaction. The transaction will require the approval of the stockholders of SWAG III and Nogin, the effectiveness of a registration statement to be filed with the Securities and Exchange Commission in connection with the transaction, satisfaction of the minimum cash condition, which is equal to $50M in gross proceeds, and the satisfaction of other customary closing conditions. The transaction is expected to close in the second quarter of 2022.

16:33 EST Raytheon Technologies appoints Christopher Calio as COO - Raytheon Technologies appointed Christopher Calio as COO and named Shane Eddy to succeed Calio, currently COO at Pratt & Whitney, as president of its Pratt & Whitney business unit, effective March 1. Calio has spent the past decade in aerospace and defense. Shane Eddy replaces Calio as president of Pratt & Whitney. Eddy joined Pratt & Whitney in 2016, with prior experience at GE Aviation, Sikorsky Aircraft Corporation and Bell Textron.

16:32 EST Humana selected by LDH to serve Medicaid beneficiaries - Humana has been notified by the Louisiana Department of Health, LDH, that the LDH intends to award a contract to Humana to deliver health care coverage to Medicaid beneficiaries across the state. Humana's Medicaid division - Humana Healthy Horizons - expects to begin administering the coverage in Louisiana later this year, pending the state's completion of its standard protest period. "We are deeply committed to increasing access to care and improving health outcomes of Louisianans who have faced numerous public health crises, natural disasters, and other challenges over the course of the pandemic," said Humana Medicaid President John Barger. "It is an honor and privilege to be chosen by The Louisiana Department of Health to serve people across Louisiana. We will provide those covered by Medicaid holistic care that prioritizes both their physical and mental well-being. And we are excited to bring our data-enabled population health model along with Humana's rich history of innovation to the Louisiana Medicaid program."

16:29 EST Service Corp. sees FY22 capital improvements $270M-$290M - Sees FY22 net cash provided by operating activities excluding special items $675M-$725M.

16:28 EST Larimar Therapeutics down 48% after FDA maintains clinical hold on CTI-1601 - Shares of Larimar Therapeutics are down $3.99, or 48% to $4.38 in after-hours trading after the company announced that the FDA is maintaining its clinical hold at this time on Larimar's CTI-1601 program and that additional data is needed to resolve the clinical hold.

16:26 EST Berkshire Hathaway adds to Chevron position, decreases stake in AbbVie - Warren Buffett's Berkshire Hathaway disclosed in an SEC filing its holdings as of December 31, 2021. Berkshire Hathaway's three new buys during the fourth quarter included, by size of position, Nubank (NU) and Activision Blizzard (ATVI). Berkshire Hathaway exited two positions during the quarter, including by size of previous position, Teva (TEVA) and Sirius XM Holdings (SIRI). Berkshire Hathaway increased its stake in four holdings, including by size of previous position, Chevron (CVX), Floor & Decor (FND), and RH (RH). Berkshire Hathaway reduced its stake in eight holdings, including by size of previous position, AbbVie (ABBV), Bristol-Myers Squibb (BMY), Charter Communications (CHTR), Marsh & McLennan (MMC), and Visa (V). Berkshire Hathaway's top holdings as of December 31, 2021, in order of size, were Apple (AAPL), Bank of America (BAC), American Express (AXP), Coca-Cola (KO), and Kraft Heinz (KHC).

16:25 EST Continental Resources sees FY22 CapEx $2.3B - The Company is projecting a $2.3 billion capital expenditures budget, excluding Franco Nevada's share of mineral costs. The Company is allocating approximately $1.8 billion to D&C activities and an additional $500 million is being allocated to non-D&C capital, planned to be primarily for leasehold, mineral acquisitions, workovers and facilities. The capital expenditures budget includes a 15% increase to legacy spending in the Bakken and Anadarko Basins combined with an approximately $500 million increase attributed to the Company's recently acquired positions in the Permian and Powder River basins. The 2022 capital expenditures budget is projected to generate approximately $5.2 billion of cash flow from operations and $2.9 billion of free cash flow (non-GAAP) for full-year 2022 at $80 per barrel WTI and $3.50 per Mcf Henry Hub. The Company is projecting approximately 15% free cash flow yield (non-GAAP). The Company is projecting an approximately $30 WTI free cash flow breakeven price. A $5 increase per barrel WTI is estimated to increase annual cash flow by approximately $300 million. The Company is projecting approximately 21% return on capital employed for 2022. The Company is targeting less than 1.0x net debt (non-GAAP) to EBITDAX (non-GAAP) by year-end 2022 or earlier. Annual crude oil production is projected to range between 195 to 205 MBopd. Annual natural gas production is projected to range between 1,040 to 1,140 MMcfpd. At year-end 2022, the Company projects a working backlog of approximately 175 gross operated wells in progress in various stages of completion.

16:23 EST Omnicell's portfolio of Advanced Services solutions selected by UMC Health - Omnicell announced that UMC Health System, UMC, in Lubbock, Texas, has selected Omnicell's portfolio of Advanced Services solutions to "support key pharmacy initiatives, including acute care, outpatient, retail, and 340B program strategies," the company said. UMC has signed a 10-year sole source agreement for Omnicell's cloud-based portfolio of solutions, including central pharmacy automation and point of care dispensing systems. The partnership is also expected to support UMC's goals of expanding community pharmacy services through opportunities with Omnicell's 340B services and EnlivenHealth's patient engagement solutions. "As medication management becomes more complex, we believe health systems need end-to-end, cloud-based solutions that will allow them to work smarter, while supporting safe, efficient pharmacy care," said Scott Seidelmann, executive vice president and chief commercial officer at Omnicell. "We're confident that Omnicell's partnership with UMC will provide comprehensive solutions that bridge acute and ambulatory care to help enhance performance and that are designed to deliver the highest levels of patient safety across the health system."

16:19 EST Brookdale Senior Living sees FY22 adjusted EBITDA $240M-$260M - Sees FY22 RevPAR growth 10%-12%.

16:15 EST Procept BioRobotics announces five year results from WATER study - Procept BioRobotics announced five-year results from its 181 patient randomized WATER study comparing Aquablation therapy to TURP, the historical standard of care for treating BPH. WATER is the only prospective, randomized, double-blind, multicenter FDA pivotal study comparing the safety and efficacy of Aquablation to TURP. The study proved superior safety due to low irreversible complications and also superior symptom relief for prostates in the range of 50 milliliters or greater. At five years, IPSS scores improved by 15.1 points in the Aquablation group and 13.2 points in TURP. However, for men with larger prostates greater than 50 milliliters, IPSS reduction was 3.5 points greater across all follow-up visits in the Aquablation group compared to the TURP group. Improvement in peak urinary flow rate was 125% and 89% compared to baseline for Aquablation and TURP, respectively. Retreatment rates, defined as needing BPH medication or surgical intervention, was approximately 1% per year for Aquablation, which was a 51% reduction compared to TURP.

16:13 EST Larimar Therapeutics receives FDA feedback on CTI-1601 program - Larimar Therapeutics announced that it has received feedback from the FDA regarding the clinical hold on Larimar's CTI-1601 program. FDA stated it is maintaining its clinical hold at this time and that additional data is needed to resolve the clinical hold. Larimar is further analyzing previously completed studies, and is evaluating if additional studies are warranted. The company also intends to engage FDA to determine how best to provide these data. Larimar is currently reassessing guidance on the timing of the planned Jive open-label extension and pediatric multiple-ascending dose clinical trials as it works to meet the agency's request. The CTI-1601 program was placed on a clinical hold by the FDA following the company's notification to the agency of mortalities which occurred at the highest dose levels in a 26-week non-human primate, or NHP, toxicology study that was designed to support extended dosing of patients with CTI-1601. At the time of the notice, Larimar had no interventional clinical trials with patients enrolled or enrolling. The recent feedback from the FDA follows Larimar's submission of a complete response including a comprehensive study report from the 26-week NHP toxicology study. Data from the Phase 1 single- and multiple-ascending dose, or MAD, clinical trials indicated that repeated subcutaneous injections of CTI-1601 were generally well tolerated at doses up to 100 mg administered daily for up to 13 days. No serious adverse events, important medical events, or treatment-related severe adverse events were reported in the trial and the number and severity of adverse events did not increase with increasing exposure to CTI-1601. The most common adverse events were mild and moderate injection site reactions. Data from the MAD trial also showed that daily subcutaneous injections of CTI-1601 at doses of 50 mg or 100 mg resulted in frataxin levels in peripheral tissues that were at or in excess of those that would be expected in phenotypically normal heterozygous carriers.

16:09 EST ADP elects David Goeckeler to Board of Directors - ADP (ADP) announced that David Goeckeler has been appointed to the Board of Directors, effective February 14. This appointment expands the number of independent outside directors on the ADP Board to 11 members. Goeckeler is CEO of Western Digital (WDC).

16:05 EST Blucora issues statement in response to Engine Capital director nominations - Blucora issued the following statement in response to the announcement by Engine Capital regarding its notice of nomination of directors for election to Blucora's board of directors at the 2022 annual meeting of stockholders: "Blucora's management and our Board have been actively engaging with our stockholders over the last year, discussing the progress we are making on our transformation as well as important governance, board composition and compensation matters. We have solicited and received input from many of the Company's largest stockholders on these topics and highly value our relationships with them. Engine bought its first share of Blucora stock in December 2021 and has sought to engage with us only very recently, mostly to gain a basic understanding of our business. Prior to delivering its notice of nomination of directors, Engine did not provide us with any substantive feedback or views about how the Company could create additional value for stockholders. We would have welcomed, and continue to welcome, any input Engine has for us. In fact, five days ago, the Chair of our Board reached out to Engine's principal, Arnaud Ajdler, seeking to have a conversation and offering a meeting with members of the Board; Mr. Ajdler responded only today and only after Engine issued its press release. Engine delivered notice of its intent to nominate four people to our Board, seemingly to replace half of the Company's current independent directors. In doing so, Engine's principal, Mr. Ajdler, made representations regarding his contacts and discussions with former directors and officers denying he had conversations with any of them regarding various material matters. Mr. Ajdler's statements are irreconcilably contradicted by statements made under oath by one of our former directors and officers during the course of an ongoing legal matter. In fact, the sworn statements revealed that Mr. Ajdler had engaged in a series of discussions regarding the topics covered by the director and officer questionnaire (including scheduling to discuss those topics) on December 6, 2021, December 7, 2021, December 8, 2021, December 11, 2021, December 13, 2021, January 3, 2022, January 12, 2022 and January 17, 2022. Mr. Ajdler's responses failed to reveal any of those discussions. It was Mr. Ajdler's gross misrepresentations that led our Board to both reject Mr. Ajdler's nomination and question his integrity and suitability to serve as a director on our Board. Engine, for its part, has now withdrawn Mr. Ajdler's nomination and continues to make misrepresentations about the extent to which Mr. Ajdler has had substantive conversations with our former directors and officers in advance of launching a proxy fight. That said, we have repeatedly sought to interview Engine's other nominees, so that our Board can determine if they would be additive to the experiences, skills and diversity of perspectives of our current directors. We continue to offer Engine and its nominees the opportunity to meet with our Board members so that we may evaluate them prior to finalizing our nominations. Our Board actively reviews the Company's corporate strategy, business configuration and performance to ensure the Company maximizes long-term value for all stockholders. We are pleased with the strong momentum of both our wealth management and tax software businesses, which allowed us to recently expand our share repurchase authorization and increase our financial guidance. We believe Blucora is on the right path. The Board will provide stockholders with recommendations with respect to each of the items that will be on the agenda at Blucora's 2022 annual meeting of stockholders in Blucora's definitive proxy statement. Stockholders do not need to take any action at this time."

16:03 EST Novavax: Singapore HSA issues interim authorization for Novavax COVID-19 vaccine - Novavax announced that the Singapore Health Sciences Authority has issued interim authorization for Nuvaxovid COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. The vaccine, also known as NVX-CoV2373, is the first protein-based vaccine to be authorized for use in Singapore.

16:00 EST Software Acquisition Group III Inc trading halted, news pending

15:01 EST AST SpaceMobile says it's teaming with 'leading mobile network operators' - AST SpaceMobile (ASTS) said it is teaming up with "leading mobile network operators" to work to provide cellular broadband coverage across the globe. In a tweet, AST SpaceMobile noted that it is working with Vodafone (VOD) in this effort, linking a video where Vodafone CTO Johan Wibergh claiming that AST SpaceMobile could help Vodafone's 300M plus subscribers. Reference Link

14:31 EST FirstService raises quarterly dividend 11% to 20.25c per share - FirstService Corporation announced that its Board of Directors has approved an 11% increase in the quarterly cash dividend on the outstanding Common Shares of the company over the previous 18.25c per Common Share and declared a quarterly dividend of 20.25c per Common Share. The dividend is payable on April 7, 2022 to holders of Common Shares of record at the close of business on March 31, 2022. The company's dividend will be 81c on an annualized basis, up from 73c during the past year.

14:07 EST Biofrontera AG to delist ADS from Nasdaq - Biofrontera AG (BFRA) announced that it has decided its American Depositary Shares, or "ADS," should be delisted from the Nasdaq Capital Market and its reporting obligations with the Securities and Exchange Commission should be deregistered and terminated. "The main purpose of the delisting is to reduce complexity in financial reporting and administrative costs. Biofrontera AG intends to maintain an amended ADS program on a Level I basis, which will allow investors to continue to hold their securities in the form of ADSs and trade the ADS on the U.S. over-the-counter market. The ADSs will automatically transition to the new ADS program in connection with the delisting and will be traded under a new ticker to be designated. Biofrontera AG's ordinary shares will continue to trade in the Prime Standard at the Deutsche Borse under the symbol B8F. Holders of ADSs may choose to exchange their ADSs to holding ordinary shares listed on the Deutsche Borse. Further details regarding the procedures will be announced later. The Company plans to submit a Form 25 relating to its ADSs on Nasdaq to the SEC on or about February 24, 2022 to initiate the delisting and expects the delisting to be become effective not less than ten days later," the company stated.

13:27 EST Griffon urges shareholders to vote for company's director nominees - The company said, "The Board of Directors of Griffon Corporation urges shareholders to protect the future of the Company and the value of their investment by voting the WHITE proxy card "FOR" all four of the Company's highly qualified director nominees and the other items of business outlined in Griffon's proxy." The Company responded to Voss Capital's press release from February 14, 2022 with the following statement: "Griffon has read Charles Diao's biography, but has Voss Capital? Voss' proxy touts Mr. Diao as 'currently serv[ing] as Managing Director of Diao & Co. LLC, a provider of advisory services'. However, DiaoCo is inactive having failed to pay its franchise tax and it has no listed phone number. Why has Voss misrepresented what Mr. Diao is doing for a living?" The Company continued, "Charles Diao is on the Board of Directors of a vaping and tobacco products company. The policies of Griffon's businesses generally prohibit the use of tobacco on company premises, and our businesses generally cover the cost of programs to help tobacco users quit smoking. How will Mr. Diao reconcile his commitment to vaping and tobacco use with Griffon's commitment to worker health and safety?" Today, Griffon is filing an Updated Summary Investor Presentation highlighting that it has repositioned the Company, continued to improve performance, and delivered strong total shareholder returns, outperforming both peers and the indices in the last year and three years. The Board encourages all shareholders to protect their investment and vote the WHITE card for growth, regardless of how many shares they hold.

12:16 EST Apple fined EUR 5M by Dutch regulator over dating app rules - The Netherlands Authority for Consumers and Markets said, "The Netherlands Authority for Consumers and Markets has concluded that the revised conditions that Apple has imposed on dating-app providers are unreasonable, and create an unnecessary barrier. The new conditions stipulate that dating-app providers must develop a completely new app if they wish to use an alternative payment system. Apple has informed ACM about these new conditions. App providers cannot adjust their existing apps. ACM finds this to be an unreasonable condition that is at odds with the requirements that Apple had set out. ACM is of the opinion that, as such, Apple still does not comply with ACM's requirements. Apple must therefore pay another EUR 5M. The total of all penalty payments currently stands at EUR 20M... In its revised conditions, Apple imposes a considerable number of conditions on dating-app providers that wish to use an alternative method of payment. For example, dating-app providers must develop a new app, and submit that new app to the Apple App Store. ACM is of the opinion that this condition hurts dating-app providers. Dating-app providers that opt for an alternative payment system are thus forced to incur additional costs. And consumers that currently use the app have to switch to the new app before they are able to use the alternative method of payment. It will cost app providers a lot of time and effort to inform consumers properly about such a change. For example, consumers will have to delete the old app, and install the new one. In addition, ACM has doubts about several other elements of the revised conditions that Apple has imposed on dating-app providers." Reference Link

12:01 EST Weber falls -11.8% - Weber is down -11.8%, or -$1.23 to $9.21.

12:01 EST Modiv falls -23.5% - Modiv is down -23.5%, or -$16.00 to $52.00.

12:00 EST Vtex rises 13.3% - Vtex is up 13.3%, or $1.01 to $8.59.

11:25 EST Asana up after CEO Moskovitz buys 1.25M shares - In a regulatory filing late on Friday, Asana disclosed purchases of its common stock that were made by President, CEO and Chair Dustin Moskovitz from February 9 to February 11. Over the three day period, Moskovitz purchased 1.25M shares of Asana Class A common stock, the filing shows. In Monday morning trading, Asana shares are up $5.39, or 9%, to $66.95.

10:54 EST RumbleON says RideNow co-founders Mark Tkach, Bill Coulter step down - RumbleOn unveiled a new unified management structure aimed at strengthening the customer experience and supporting future growth and drive long term improvements to the overall customer experience. RumbleOn has promoted Lyle Kramper as National Senior Vice President of Retail and Kristopher Price as National Director of Manufacturer Relations. As National Senior Vice President of Retail, Kramper will oversee a slate of Regional Directors who will lead the daily operations of multiple facilities based primarily on geographic location. RumbleOn also announced that RideNow's co-founders, Mark Tkach and Bill Coulter, have stepped down from their positions with RumbleOn effective February 11, 2021. Subsequent to RumbleOn and RideNow's business combination, which closed August 31, 2021, Tkach served as a director and RumbleOn's COO and Coulter served as Executive Vice Chairman of the Board. Peter Levy, RumbleOn's President, has been appointed to succeed Mr. Tkach as RumbleOn's COO. Mr. Levy has been a member of RumbleOn's senior management team since August of 2017 and was appointed to its Board of Directors in June of 2021.

10:01 EST Juniper acquires WiteSand, terms not disclosed - Juniper Networks announced that the company has acquired WiteSand, a cloud-native zero trust Network Access Control solutions company. This deal brings a highly experienced engineering team and exceptional technology to Juniper, accelerating the company's ongoing efforts to deliver a next-generation NAC solution as a key element of their award-winning AI-driven enterprise portfolio.

10:01 EST Sea Limited falls -14.9% - Sea Limited is down -14.9%, or -$23.66 to $134.62.

10:00 EST Vtex rises 7.7% - Vtex is up 7.7%, or 58c to $8.16.

10:00 EST Cornerstone Building Brands rises 24.9% - Cornerstone Building Brands is up 24.9%, or $4.59 to $22.99.

09:47 EST Full Truck Alliance falls -5.7% - Full Truck Alliance is down -5.7%, or -49c to $8.15.

09:47 EST Weber falls -14.7% - Weber is down -14.7%, or -$1.53 to $8.91.

09:47 EST Bloom Energy rises 6.2% - Bloom Energy is up 6.2%, or $1.05 to $17.93.

09:46 EST MDV Stock trading resumes

09:41 EST MDV Stock trading halted, volatility trading pause

09:38 EST Gravity trading resumes

09:29 EST Asure Software files for over $200M in ERTC stimulus on behalf of clients - Asure Software announced they have filed for more than $200 million in stimulus on behalf of their clients as part of the Employee Retention Tax Credit program.

09:23 EST Midland Holdings to use Matterport digital twins for virtual 3D experiences - Matterport announced that Midland Holdings, one of the largest residential real estate brokerages in the Greater China region, will become the first brokerage in the region to use Matterport digital twins to create virtual 3D experiences for its entire portfolio of properties. Using Matterport, the company will provide its customers with easy-to-use, 3D versions of its network of properties through China, Hong Kong, and Macau while also realizing significant operational improvements and cost savings.

09:10 EST FIS announces acquisition of Atlanta-based, Payrix, terms undisclosed - Financial technology leader FIS announces it has enhanced its embedded payments strategy with the acquisition of Atlanta-based, Payrix. This acquisition aligns with FIS' strategy to expand its e-commerce offerings to companies of all sizes, and in any industry, by embedding payments capabilities within Software-as-a-Service platforms. This acquisition will also enable FIS to unlock the value of its broad solution portfolio by delivering embedded finance capabilities in addition to its e-commerce offerings to small- and medium- sized businesses . "Since acquiring Worldpay in 2019, FIS continues to expand its strategic payments capabilities and offerings in global e-commerce," said Stephanie Ferris, President, FIS. "Bringing the Payrix capabilities inside FIS enables us to continue our journey of serving e-commerce as well as platform companies. The acquisition of Payrix is an excellent proof point of FIS' ability to unlock the value of our broad portfolio of solutions as companies of all sizes rely on FIS as a destination for innovation to advance how the world pays, banks and invests." Terms of the deal are not disclosed. The acquisition is not expected to be material to FIS' financial results to be announced on Feb. 15.

09:08 EST Varian Biopharmaceuticals to become public via SPK Acquisition merger - Varian Biopharmaceuticals and SPK Acquisition announced it has entered into a definitive merger agreement for a business combination that will result in Varian Bio becoming a publicly traded company. Varian Bio is developing a high-potency, specific atypical protein kinase C iota inhibitor that has the potential to be best-in-class as a treatment for various oncology indications with an initial focus on basal cell carcinoma and molecularly targeted solid tumors. Varian Bio is developing rationally designed aPKCi small molecule inhibitor candidate that has been optimized for potency, selectivity and tolerability. aPKCi has been implicated as an oncogene in a number of human cancers, including BCC, cutaneous T-cell lymphoma, non-small cell lung cancer, acute myeloid leukemia, colorectal cancer, and pancreatic cancer, among others. aPKCi has also been demonstrated to have a role in allowing the immune system to recognize tumors, recruit immune cells into the area, and ramp up the anti-tumor response to kill cancer cells in the lab by shrinking their tumors. Varian Bio's leadership team and scientific advisory board has extensive experience in the development of novel cancer therapeutics. including Jeffrey B. Davis, a serial entrepreneur with over two decades of experience in the biotechnology and specialty pharmaceuticals industry, and Jonathan Lewis, M.D., Ph.D., Chairman of Scientific Advisory Board, a surgical oncologist and cancer researcher. The active pharmaceutical ingredient in VAR-101/102, an aPKCi inhibitor, has demonstrated dose dependent anti-tumor activity in murine and human BCC cell lines, as well as other cancer models. Varian Bio intends to develop VAR-101 in a topical formulation for BCC which has the potential to offer optimal clinical utility in BCC as a surgical neoadjuvant or adjuvant therapy. VAR-102, an oral formulation of the active aPKCi inhibitor, lends itself to broader applications in multiple tumor types. Varian Bio believes that VAR-101 and VAR-102, if approved, could represent significant medical and commercial opportunities. Varian Bio, together with its collaborators, is initially developing two formulations of its lead aPKCi inhibitor that has been selected for potency, selectivity, biomarker activity and low toxicity in murine and large animal models. VAR-101 is a dermatologic gel formulation of for the potential topical treatment Basal Cell Carcinoma. BCC is the most common human cancer in the World. There are 4.3 million cases of BCC diagnosed in the US each year, more than one million of whom undergo Mohs surgery. While Mohs has a low recurrence rate, the surgical approach is costly, time consuming, and can be disfiguring, requiring complex reconstructive surgery. Mohs surgery is the 5th most expensive and costly cancer treatment for Medicare in the United States. The active aPKCi inhibitor has demonstrated dose-dependent in vitro BCC cell killing with concordant biomarker Gli-1 mRNA knockdown. Gli-1 is present in BCC, but not normal basal cells and increases in hedgehog pathway inhibition resistance. VAR-102 is an oral formulation of the aPKCi inhibitor for the potential treatment of multiple solid tumors, including non-small cell lung cancer, pancreatic, colorectal and other tumor types. An increasing body of scientific evidence implicates aPKCi as playing a central role in cancer cell growth and metastasis. Varian will pursue systemic tumor indications in a "basket" solid tumor Phase 1 trial. Molecular targeting and target engagement will be measured with associated biomarker exploration. Pursuant to the merger agreement, Varian Bio will merge with a wholly owned subsidiary of SPK, with Varian Bio being the surviving entity of the merger and a wholly owned subsidiary of SPK. SPK, which currently holds approximately $50 million in gross proceeds from the trust account, will be renamed Varian Biopharma, Inc. following the merger. The cash proceeds from the transactions are expected to fund manufacturing, pre-clinical and IND-enabling toxicology studies, and "first-in-human" human clinical studies for an aPKCi inhibitor. This will include the continued development of VAR-101, a topical formulation of its lead aPKCi compound, for the treatment of BCC, and the development of VAR-102, an oral formulation thereof, for the treatment of solid malignancies. Following the closing of the transaction, the Company will be led by existing management from Varian Bio, including CEO Jeffrey B. Davis and CMO Dr. Jonathan Lewis. The transaction has been approved by the Boards of Directors of both SPK and Varian Bio and is subject to the satisfaction of customary closing conditions, including the approval of SPK's shareholders. The transaction is expected to close in the second quarter of 2022.

09:07 EST Eagle Point Credit boosts Q2 dividend 17% - Eagle Point Credit Company announces the declaration of distributions on shares of the Company's common stock. The Company has declared three separate distributions of 14c per share on its common stock, an increase of 17% from its previous monthly distribution rate of 12c per share, payable on each of April 29 May 31 and June 30 to stockholders of record as of April 11 May 11 and June 10 respectively. The following schedule applies to the distributions: Distributions on common stock are generally paid from net investment income and may also include capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Company's stockholders on Form 1099 after the end of the 2022 calendar year. "We are pleased to be able to increase our monthly distribution by 17% to 14c per common share," said Thomas Majewski, Chief Executive Officer. "This further underscores the continued strength of our financial performance and our confidence in the Company's investment portfolio and future prospects."

09:05 EST Fresh Vine expands distribution to two new states - Fresh Vine Wine announced that it has expanded distribution to two new states, Michigan and New Jersey. These new states add to Fresh Vine Wine's rapid, nationwide expansion, one of the Company's key strategic priorities. The Company also has a complementary, rapidly expanding direct-to-consumer distribution channel.

09:04 EST Novavax files for CMA of COVID-19 vaccine in Switzerland - Novavax announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional marketing authorization of NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant, for use in adults.

09:02 EST Avalon GloboCare expands cellular immuno-oncology platform - Avalon GloboCare announced that the Company is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor - Natural Killer, CAR-NK, cell therapies. Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors. Avalon plans to expand its clinical program in collaboration with its major clinical trial partner, the Lu Daopei Hospital. The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate, part of the Company's proprietary mRNA-based FLASH-CAR platform. AVA-011 is currently at the IND-enabling, process development stage, which is expected to produce clinical-grade CAR-T cells for an upcoming clinical trial in patients with hematological malignancies. To further strengthen its CAR-NK development capabilities, Avalon has appointed Dr. Dongfang Liu to its Scientific and Clinical Advisory Board.

08:58 EST Home Point enters servicing relationship with ServiceMAc - Home Point Financial Corporation announced an agreement with ServiceMac to handle Homepoint's servicing operations. With this arrangement, Homepoint's servicing associates will have the opportunity to join the ServiceMac team and provide Homepoint's customers and broker partners with the same high-quality service they are accustomed to from the same highly skilled team that serves them today. This continuity is especially important as customers exit agency-supported forbearance programs. Additionally, customers will continue to see the Homepoint brand on all communications, supporting a seamless transition.

08:43 EST AMD board of director elects CEO Su as chair, appoints Olson, Vanderslice - AMD announced that the AMD board has elected President and CEO Dr. Lisa Su as the chair of the board and John Caldwell as lead independent director. Caldwell joined the AMD board in 2006 and has served as chair since May 2016. AMD also announced that former Xilinx board members Jon Olson and Elizabeth Vanderslice have joined the AMD board in conjunction with the close of AMD's acquisition of Xilinx.

08:42 EST AMD completes acquisition of Xilinx - AMD (AMD) announced the completion of its acquisition of Xilinx (XLNX) in an all-stock transaction. AMD expects the acquisition to be accretive to non-GAAP margins, non-GAAP EPS and free cash flow generation in the first year. "The acquisition of Xilinx brings together a highly complementary set of products, customers and markets combined with differentiated IP and world-class talent to create the industry's high-performance and adaptive computing leader," said AMD President and CEO Dr. Lisa Su. "Xilinx offers industry-leading FPGAs, adaptive SoCs, AI engines and software expertise that enable AMD to offer the strongest portfolio of high-performance and adaptive computing solutions in the industry and capture a larger share of the approximately $135 billion market opportunity we see across cloud, edge and intelligent devices." Former Xilinx CEO Victor Peng will join AMD as president of the newly formed Adaptive and Embedded Computing Group. Upon close, Xilinx stockholders received 1.7234 shares of AMD common stock and cash in lieu of any fractional shares of AMD common stock for each share of Xilinx common stock. Xilinx common stock will no longer be listed for trading on the NASDAQ stock market.

08:40 EST Apollo Funds to acquire additional shares of ABC Technologies Holdings - AP IX Alpha Holdings, an affiliate of certain funds managed by affiliates of Apollo Global Management, announced that, on February 11, 2022, it entered into purchase agreements to purchase up to 10,000,000 common shares of ABC Technologies Holdings from affiliates of Coliseum Capital Management. Under the terms of the Agreements, the Purchaser will acquire 5,000,000 Common Shares and if the Seller participates in ABC's rights offering, the 5,000,000 Common Shares that may be issued to the Seller pursuant to the Rights Offering. The Purchaser will pay CAD$6.25 for each Common Share acquired, representing aggregate consideration of CAD$62,500,000.00 for both the Initial Transaction Shares and the Rights Shares. The Apollo Funds and their affiliates currently beneficially own or control, directly or indirectly, 31,168,685 Common Shares, representing approximately 53.9% of the 57,790,064 issued and outstanding Common Shares on a non-diluted basis. Following the closing of the Rights Offering and the transactions contemplated by the Agreements and assuming the Apollo Funds maintain their 53.9% ownership of ABC, and the Apollo Funds acquire the Rights Shares, the Apollo Funds and their affiliates will beneficially own or control, directly or indirectly, 72,337,370 Common Shares, representing approximately 62.6% of the issued and outstanding Common Shares on a non-diluted basis. The Purchaser holds the Common Shares for investment purposes. Subject to compliance with applicable laws, the Apollo Funds or their affiliates may determine to purchase additional Common Shares, or sell all or some of the Common Shares they will hold, either on the open market or in private transactions, depending upon the price of the Common Shares, market conditions, economic conditions and other factors. Apollo may formulate other purposes, plans or proposals regarding the Corporation, any of its subsidiaries or any of their respective securities or may change its intention with respect to any and all matters referred to above.

08:39 EST Point Biopharma provides early-stage program updates - POINT Biopharma Global provided progress updates on its early-stage programs, including the pan-cancer fibroblast activation protein-alpha inhibitor program PNT2004, and the next-generation actinium-225 PSMA targeted program PNT2001. PNT2004: Initiation of a Phase 1 therapeutic dose-escalating clinical trial planned for summer 2022 - POINT accelerated PNT2004's therapeutic program after the compelling preclinical data for PNT2004's lead candidate PNT6555 was first announced in Q4 2021. The Company recently completed a pre-CTA meeting with Health Canada regarding the development pathway and clinical study design for the upcoming Phase 1 trial, and expects to file a CTA with Health Canada at the end of Q1 2022. The clinical trial is expected to commence in summer 2022 in Canada. PNT2001: IND-enabling studies with actinium-225 planned for 2022, IND/CTA filing expected H1 2023 - Pre-clinical studies of PNT2001 have resulted in the identification of a lead candidate which, as compared to late-stage PSMA ligands, demonstrates potent anti-tumor activity using Ac-225, while also having an improved safety profile. The Company has advanced the lead candidate into IND-enabling studies which are expected to support an IND/CTA submission in H1 2023. CanSEEK Prodrug Technology Platform: Early-stage ligands against different targets are in development - The goal of the CanSEEK program is to significantly improve the precision and safety of radioligands. Based on the -Ala-Pro FAP-alpha substrate technology, CanSEEK prevents a radioligand from binding to receptors until it has been activated by FAP-alpha in the tumor microenvironment.

08:37 EST Eagle Point Income Company increases monthly distributions 4% to 12.5c per share - The company has declared three separate distributions of 12.5c per share on its common stock, an increase of 4% from its previous monthly distribution rate of 12c per share, payable on each of April 29, May 31 and June 30 to stockholders of record as of April 11, May 11 and June 10 respectively.

08:35 EST Knightscope announces strategic partnership with Allied Universal - Knightscope announced a strategic partnership with Allied Universal, a global security and facility services company with revenues at approximately $20B and more than 800,000 employees worldwide, to provide Autonomous Security Robots, or ASRs, to the company's U.S.-based customers to help deter crime, enhance situational awareness and improve security professional safety.

08:34 EST IronNet in stock purchase pact with Tumim Stone for up to $175M - IronNet announced that it has entered into a common stock purchase agreement with Tumim Stone Capital. Under the terms of the Purchase Agreement, IronNet has the right, but not the obligation, to sell to Tumim Stone up to $175M of its common stock, subject to certain conditions. IronNet may direct Tumim Stone to purchase a number of shares not to exceed an amount determined by IronNet's trading volume and stock price. Purchase notices may be issued over the period commencing once certain customary conditions are satisfied, including the filing and effectiveness of a registration statement with the U.S. Securities and Exchange Commission with respect to resale of the shares issued pursuant to the Purchase Agreement, and ending on the first day of the month next following the 36-month anniversary of the Purchase Agreement. Further details will be contained in a Current Report on Form 8-K to be filed by IronNet with the SEC. IronNet expects to use net proceeds from any sales of common stock under the Purchase Agreement for working capital and general corporate purposes to support its future growth.

08:33 EST CIM Commercial Trust signs long-term lease in Los Angeles - CIM Commercial Trust announced that it has signed a long-term lease with Lisson Gallery for the entire approximately 5,000-square-foot building at 1037 N. Sycamore Ave. in Los Angeles. Established in 1967, Lisson Gallery is an international contemporary art gallery with locations in London, New York, and Shanghai. The space at 1037 N. Sycamore will serve as Lisson Gallery's first location in Los Angeles, which is anticipated to open in Autumn 2022.

08:32 EST iPower announces launch of new joint venture, Global Social Media - iPower has entered into a joint venture with certain individuals and a social media marketing and entertainment company to create a social commerce platform, Global Social Media. The Company's JV partners bring social media marketing expertise to the venture and iPower will provide its supply chain and e-commerce expertise. iPower also plans to leverage GSM for its own benefit in driving global brand and product awareness through media platforms. iPower will contribute $100,000 for a 60% equity interest in the JV, in accordance with the terms of the JV agreement. "Social commerce is the fastest growing category in the e-commerce industry and we are keen to participate in that growth," said iPower CEO Lawrence Tan. "Similar to our recently launched logistics joint venture, we have identified another low-cost opportunity to enter a new services category that can also benefit our own hydroponics business. Our partners will leverage their expertise in social media marketing to build a strategic network of global influencers that we can utilize to increase iPower's brand awareness and geographic exposure. We look forward to growing this venture and our new line of services in 2022 and beyond."

08:22 EST Trinity Biotech announces WHO approval of TrinScreen HIV - Trinity Biotech has received approval for its new HIV screening product, TrinScreen HIV, from the World Health Organisation, WHO. TrinScreen HIV: Trinity Biotech's Uni-Gold HIV product has been the main confirmatory test provider for the detection of the HIV virus on the African continent over many years. Trinity Biotech has developed this new product, TrinScreen HIV, specifically for the screening market, a market that is significantly larger than the confirmatory market, with an estimated market size of over $150M. The Company will manufacture TrinScreen(TM) HIV at its automated manufacturing plant in Bray, Ireland. Commenting, Ronan O'Caoimh, Chief Executive Officer stated, "We are excited to have received WHO approval for our new HIV screening product, TrinScreen HIV. This product has been a strategic priority for Trinity Biotech over several years and this approval is a very positive development for the company's future. We have already earned a strong reputation in the HIV testing market in Africa with our HIV confirmatory test, Uni-Gold HIV. We believe that with TrinScreen HIV, we are ideally positioned to take a significant share of the HIV screening market in Africa given the excellent clinical performance of the product and our existing strong reputation in the HIV testing market in Africa."

08:21 EST Whitestone REIT announces leadership transitions - Whitestone REIT announced several leadership transitions, effective immediately. Leadership Transitions: Promotions: Christine Mastandrea, Executive Vice President of Corporate Strategy, has been appointed Chief Operating Officer and will assume the responsibilities of this role in addition to the ones she has currently. Peter Tropoli, General Counsel, has been appointed Corporate Secretary and will assume the responsibilities of the position in addition to his duties as General Counsel; and Michelle Siv, Director of Human Resources, has been promoted to Vice President of Human Resources. Departures: Additionally, the Company is announcing that John Dee, COO and Bradford Johnson, Executive Vice President of Acquisitions and Asset Management, as part of the leadership transition, have left the Company, effective February 9, 2022. New Hires: Whitestone is also pleased to announce the hiring of two new members to its management team. David Mordy will become Whitestone's Director of Investor Relations, effective February 14, 2022, and Michael Ly will join the Company as its new Controller, effective February 21, 2022. New Executive Leadership Team: Following the completion of these transitions, the Company's executive leadership team will comprise: Dave Holeman, CEO; Christine Mastandrea, COO; Scott Hogan, CFO; Peter Tropoli, General Counsel; and Michelle Siv, Vice President of Human Resources.

08:19 EST Sysco completes acquisition of The Coast Companies - Sysco Corporation announced it has completed the acquisition of The Coastal Companies, a leading fresh produce distributor and value-added processer. The acquisition will operate as part of FreshPoint, Sysco's specialty produce business, and enables FreshPoint to enhance its service to the important Mid-Atlantic region, strategically diversify its portfolio by adding retail and ready-to-eat capabilities and adds state-of-the-art facilities with capacity for growth. Founded in 1992 and based in Laurel, MD, The Coastal Companies generates annual revenue of approximately $600M and is comprised of three integrated businesses: Foodservice Distribution - Coastal Sunbelt Produce a leading foodservice supplier of produce, specialty, fresh-cut and value-added products in the Mid-Atlantic region. Retail Distribution - Lancaster Foods is a wholesale supplier of produce and fresh-cut products to retail distribution centers and store locations. Value-Added Manufacturing - East Coast Fresh is a regional processor of fresh-cut and value-added products, manufacturing items such as pre-cut fruits and vegetables, salsas, meal preparation solutions and grab-and-go items. Sysco acquired The Coastal Companies from Continental Grain Company and Rabo Investments through Arlon Food and Agriculture Partners, LP, their co-sponsored private equity fund. The terms of the agreement were not disclosed.

08:17 EST Bionano Genomics appoints Klein as first Chief People Officer - Bionano Genomics (BNGO) announced that it has appointed Helene Klein as its chief people officer, further strengthening its leadership team. "The appointment of a chief people officer reflects Bionano's focus on maintaining and evolving its culture of innovative, disciplined, and rapid response to market needs," the company said. Klein was formerly the chief people officer at the Beachbody Company (BODY) where she led the people function for 14 years.

08:16 EST Stryve Foods completes first expansion of Oklahoma manufacturing facility - Stryve Foods shared details for boosting the manufacturing capacity of its Stryve Biltong and Vacadillos Carne Seca meat snack product lines. Leveraging the $35M raised last month in a private placement transaction, Stryve has bolstered its primary manufacturing facility in Madill, Oklahoma and is planning to build and/or procure other facilities during 2022. Stryve is also investing in product innovation, supply chain improvements, and expanding its marketing initiatives. "With increased focus in the U.S. on health and wellness, Stryve is experiencing strong consumer and retailer demand for its healthy meat snacks. The time is right for Stryve to invest in its future, so we are taking bold steps to meet market demand and prepare for what we believe will be a very bright future," said Joe Oblas, Co-Founder and Chief Executive Officer at Stryve. "The first major step was to expand the drying capabilities at our primary factory, which significantly increases drying capacity ahead of the large distribution expansions previously announced with Costco, Walmart and Target, among others," added Oblas. "This was completed ahead of schedule and within budget. Second, we have located a site to consolidate our fulfillment operations that will further enable Stryve to expand capacity and capture efficiencies by locating our corporate offices, e-commerce fulfillment and wholesale fulfillment under one roof. Lastly, Stryve is working on developing additional manufacturing capabilities in-house, that can support diversified growth initiatives in the future."

08:14 EST Enphase Energy, Swell Energy launch partnership with solar, battery offerings - Enphase Energy announced that it is launching a partnership with renewable energy and grid solutions provider Swell Energy. The partnership enables Enphase Energy Systems, powered by IQ Microinverters and IQ Batteries, to participate in Swell's distributed, virtual power plant, VPP, programs in California, New York, and Hawaii. The partnership will enhance solar and battery access along with choice for energy users while delivering critical resources to the local grid. It also aims to expand solar and battery deployment in key energy markets. "Together with Swell we share a mission to provide a world-class customer experience and cutting edge, smart technology," said Dave Ranhoff, chief commercial officer at Enphase Energy. "Swell's programs make it even more compelling for homeowners to choose Enphase Energy Systems, so they can reliably and efficiently run their lives on clean energy, protect against grid outages, and better manage costs."

08:14 EST CytRx highlights Orphazyme update on arimoclomol NDA - CytRx (CYTR) highlighted Orphazyme's (ORPH) announced update on the process and anticipated timelines for resubmission of its new drug application, or NDA, to the FDA for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C, or NPC. CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties. In line with recommendations from the FDA during a Type A Meeting held in October 2021, Orphazyme intends to request a Type C Meeting to discuss additional data, information and analyses addressing certain topics in the complete response letter to align on a path to resubmission for arimoclomol in NPC with the FDA. Orphazyme plans to request the Type C Meeting in Q2. Subject to these discussions, Orphazyme aims to resubmit the NDA during the second half of 2022. Separately, Orphazyme's EU Marketing Authorization Application for arimoclomol for the treatment of NPC was filed with the European Medicines Agency in November 2020. An opinion from the Committee for Medicinal Products for Human Use on this application is expected in Q1. CytRx will continue to share publicly available updates as they relate to the company's licensing deal with Orphazyme.

08:12 EST Guardion Health Sciences launches new Viactiv Omega BOOST gel bites - Guardion Health Sciences announced the launch of Viactiv Omega BOOST gel bites, the Company's first expansion of the Viactiv brand since the Company acquired it in June 2021. The 1,200 mg Omega-3 gel bites are designed to provide total body support, including cardiovascular, brain, joint and eye health. "Our new Omega Boost product is an exciting addition to our Viactiv line as it introduces a new dosage form that addresses a gap in the Omega-3 market - clinically proven levels of Omega-3 in an easy to take, great tasting product that you will look forward to taking every day," commented Bret Scholtes, Guardion's Chief Executive Officer. "Further, a study of consumer use of dietary supplements has shown strong overlap between calcium users and those who use Omega-3 supplements. We are excited to be able to offer these supportive nutrients under the same trustworthy Viactiv brand and look forward to continuing to be a reliable and sought-after resource for the nutritional supplement needs of our customers."

08:11 EST Vaxart appoints Berg as senior Vice President, General Counsel - Vaxart (VXRT) announced the appointment of Edward Berg as the Company's first in-house General Counsel, effective. Berg has practiced law for more than 30 years. He joins Vaxart from BioMarin Pharmaceutical (BMRN), where he served as VP, Deputy General Counsel since 2018.

08:10 EST McCormick announces new targets for reducing GHG emmissions - The company announced new targets for reducing greenhouse gas emissions and water use, as well as improving recycled and solid waste recovery from its facilities. "McCormick's commitment to operating sustainably beyond 2025 is also a top priority. We are underway on our journey to achieving our 1.5 degrees C greenhouse gas emission reduction by 2030 and Net Zero by 2050 targets." said Michael Okoroafor, Chief Sustainability Officer for McCormick. "With 84% of the company's plastic packaging capable of being reused, recycled, or repurposed, McCormick will continue to remain at the forefront of the industry. The company also has plans to further expand its global employee learning and development, health and wellbeing, and giving and volunteer programs to achieve its 2025 goals."

08:10 EST Telesat Holdings enters capacity deal with Anuvu - Anuvu and Telesat have announced "the largest yet in a series of satellite capacity deals, providing Anuvu and its customers with new Ka-band connectivity over the Southeastern US, the Caribbean, the Gulf of Mexico and Central America," the company said. Under the agreement, Anuvu will add approximately ten gigabits of Ka-band capacity from Telesat starting next month. "The Telesat Lightspeed LEO constellation, with its flexible capacity and 100% global coverage, was designed for mobility from the start. And Anuvu's Bridge to LEO network ensures their passengers an early and smooth upgrade path to the highest-capacity, lowest-latency, fiber-like passenger experience on Telesat Lightspeed," said Glenn Katz, Chief Commercial Officer at Telesat. "Telesat provided Anuvu's first satellite capacity over a decade ago and we are proudly further-cementing our relationship with this important agreement."

08:08 EST Bank of America launches online payment solution, 'Pay by Bank' - Bank of America announced its latest online payment solution called Pay by Bank. Launched in conjunction with Banked Ltd., this new feature allows customers of e-commerce companies, initially in the UK, to pay directly from their bank account. Pay by Bank transactions, which are based on the concept of Open Banking, take place in real-time and require no credit or debit card details. This makes online checkout simpler, faster and more secure.

08:07 EST Kinnate to deliver oral presentation on RAF Inhibitor Candidate Program - Kinnate Biopharma announced that it has been selected to deliver an oral presentation of preclinical data from its KIN-2787 program at the upcoming virtual IASLC 2022 Targeted Therapies of Lung Cancer meeting taking place February 22-26, 2022. The presentation will be delivered by study collaborator and presenting author Tadashi Manabe, M.D., Ph.D., Postdoctoral Scholar-Fellow, Department of Medicine, Division of Hematology and Oncology at the University of California, San Francisco. In this study, KIN-2787 activity was assessed by suppression of downstream MAPK pathway signaling and subsequent cell growth inhibition across BRAF-altered and/or RAS-altered versus wild type panels of human non-small cell lung cancer cell lines. In contrast to approved therapies, targeting Class I BRAF alterations, KIN-2787 was most active in Class II and Class III BRAF-altered NSCLC cells. KIN-2787 also inhibited cellular proliferation in BRAF alteration-positive human NSCLC cell lines. Additionally, KIN-2787 was active in in vitro cell growth inhibition assays against a parental BRAF Class I-driven NSCLC cell line and retained activity in an experimentally acquired vemurafenib-resistant BRAF p61 splice variant-expressing derived cell line. In vivo, KIN-2787 efficacy was evaluated using a BRAF-alteration driven human NSCLC cell line and patient-derived xenograft models. The ongoing KN-8701 trial of KIN-2787 is actively enrolling patients across multiple centers in the United States.

08:07 EST 3M to invest $165M in manufacturing facility in Cottage Grove, Minnesota - The company announced an investment of $165M to improve water quality and reduce water use at its manufacturing facility in Cottage Grove, Minnesota. In August of 2021, the company announced it would no longer use an incinerator to process waste in Cottage Grove. 3M has fully transitioned its waste management at the site to an experienced third party, and as a result, will reduce its on-site energy use by an estimated 25%. The technology investment in Cottage Grove is another step forward in the company's $1B, 20-year commitment to ambitious environmental goals, which include improved water quality, reduced water use and reduced plastic use - as well as achieving carbon neutrality by 2050.

08:07 EST Monmouth announces advisory firms recommend vote "FOR" ILPT transaction - Monmouth Real Estate Investment (MNR) announced that leading independent proxy advisory firms Institutional Shareholder Services and Glass, Lewis & Co. have recommended that shareholders vote "FOR" the previously announced all-cash transaction with Industrial Logistics Properties Trust, ILPT, (ILPT) at the Company's upcoming Special Meeting of Shareholders scheduled for February 17, 2022. "We are pleased that both ISS and Glass Lewis support our Board's unanimous recommendation that shareholders vote 'FOR' the transaction with ILPT," said Michael Landy, President and CEO of Monmouth. "The recommendations from ISS and Glass Lewis validate our belief that the proposed transaction maximizes value for shareholders, delivering immediate and certain all-cash value at a significant premium. The Monmouth Board, with the assistance of its financial and legal advisors, completed a comprehensive review process to thoroughly evaluate all strategic options available to the Company. We remain confident that ILPT's all-cash offer, which was the highest bid Monmouth received, is the best available outcome." As previously announced, Monmouth and ILPT have entered into a definitive merger agreement pursuant to which ILPT has agreed to acquire Monmouth for $21.00 per common share, which represents a 24% premium to the unaffected closing share price of $16.99 on December 18, 2020 and a 36% premium to the 30-day volume weighted average unaffected trading share price of $15.43 as of November 5, 2021.

08:06 EST 3M to commit $1B over 20 years to achieve carbon neutrality - "3M is powered by purpose, unlocking the power of people, ideas, and science, to re-imagine what's possible and create what's next," said 3M chairman and CEO Mike Roman. "We are well positioned for 2022 and beyond because of our customer-inspired innovation, industry-leading businesses, fundamental strengths, and world-class capabilities enabling us to win in fast-growing markets. "Building upon 9% organic growth in 2021, we expect to continue growing above the macro environment, while generating robust cash flow, expanding margins and strengthening our balance sheet. We continue to drive value through our strategic priorities: accelerating innovation, actively managing our portfolio, transforming our operating model with new digital capabilities and investing in our people and culture. In addition, we continue to advance our leadership in ESG, including a $1 billion commitment over 20 years to achieve carbon neutrality, reduce water use and improve water quality along with reducing the use of plastics."

08:05 EST Unity Biotechnology announces additional data from Phase 1 study of UBX1325 - UNITY Biotechnology announced that 24-week clinical data from the Phase 1 study of UBX1325 was presented by Robert Bhisitkul, M.D., Ph.D., professor of ophthalmology and director of the Retina Fellowship at University of California, San Francisco, at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference on Saturday, February 12, 2022. Consistent with previously shared data, the majority of patients treated with UBX1325 showed rapid and sustained improvements in best corrected visual acuity and maintained or improved central subfield thickness. The presentation titled, "Phase 1 Study of Intravitreal UBX1325: A Novel Agent Against Retinal Cell Senescence in AMD and DME," featured safety, efficacy, and durability data from the Phase 1 single ascending dose study of UBX1325 in patients with diabetic macular edema and wet age-related macular degeneration, including data results from the AMD expansion cohort through 24 weeks, marking the study completion: UBX1325 was well tolerated without signs of intraocular inflammation or other related ocular adversities; In DME, following a rapid improvement in BCVA, a mean improvement of 9.5 ETDRS letters from baseline at 6 months in the higher dose cohorts and 6.9 ETDRS letters from baseline at 6 months in all dose cohorts was observed; In AMD, following a rapid improvement in BCVA, there were improvements or stabilization of both BCVA and CST through 6 months post-injection; In both diseases, the majority of patients treated with UBX1325 showed durable improvement in vision and did not meet objective rescue criteria requiring standard of care anti-VEGF treatment; Among patients who received anti-VEGF rescue, there was minimal change in either mean BCVA or CST following treatment in all but one patient.

08:04 EST Eledon Pharmaceuticals provides corporate update, 2022 anticipated milestones - Eledon Pharmaceutical provided a summary of key 2021 accomplishments and previewed anticipated 2022 milestones. 2021 Key Highlights: Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart in Amyotrophic Lateral Sclerosis. Received regulatory clearance to initiate a Phase 1b clinical trial in Canada and the United Kingdom. Received regulatory clearance to initiate a Phase 2a clinical trial in Australia and New Zealand. Obtained FDA clearance to initiate a Phase 2a U.S. clinical trial in islet cell transplantation. Presented pre-clinical data demonstrating the effectiveness of tegoprubart in preventing islet cell allograft rejection. United States Adopted Names Council adopted "tegoprubart" as the unique non-proprietary or generic name for AT-1501. Anticipated 2022 Milestones: 2Q 2022: topline data from Phase 2a trial of tegoprubart in ALS. 2Q 2022: completion of non-human primate kidney transplantation study with tegoprubart. 2H 2022: initial data from Phase 1b trial of tegoprubart in kidney transplantation. 2H 2022: initial data from Phase 2a trial of tegoprubart in IgAN. 2H 2022: initial data from Phase 2a trial of tegoprubart in islet cell transplantation.

08:04 EST NuStar Energy to sell Nova Scotia terminal to EverWind Fuels for $60M - NuStar Energy announced that it has entered into an agreement to sell its terminal in Nova Scotia, Canada to EverWind Fuels for $60M. The 7.8M-barrel storage terminal is located at Point Tupper on the Strait of Canso, near Port Hawkesbury, Nova Scotia. The sale is expected to close in the first half of 2022, subject to the satisfaction of customary closing conditions. NuStar now expects to spend $130M to $160M on strategic capital and continues to expect to spend $35M to $45M on reliability capital for the year, all of which will be funded by internally generated cash flows.

08:01 EST CECO Environmental receives order for exhaust systems in Australia - CECO Environmental announced its Thermal Acoustics Business Unit's Aarding branded solutions has received an order to deliver two customer designed exhaust systems for a new clean energy, gas turbine power plant, located in New South Wales, Australia. The power plant is designed as an alternative cleaner power generator, using natural gas as the primary source. The existing coal plant will be retired once the new 660MW open-cycle plant begins commercial production in December 2023. Aarding's gas turbine exhaust systems will enable the plant to meet or exceed the strict noise abatement requirements of the Australian government.

07:47 EST Nasdaq market technology EVP Lars Ottersgard retires - Nasdaq, announced the retirement of Lars Ottersgard, Executive Vice President for Market Technology, after 16 years providing leadership to the organization. Ottersgard will transition into an advisory role on April 30, 2022, until his formal retirement on August 31. As a result, the company is appointing two senior leaders - Jamie King and Roland Chai - to drive forward its Anti-Financial Crime and Market Infrastructure Technology businesses, respectively, and both will report directly to Nasdaq President and CEO Adena Friedman. The announced changes are not expected to impact the company's public financial reporting structure for the Market Technology segment, comprised of the Anti-Financial Crime and the Market Infrastructure Technology businesses. Additionally, Nasdaq continues to maintain its financial and operational performance targets for the Market Technology segment. The following leadership changes will be effective from April 4, 2022: Jamie King will be elevated to Executive Vice President, Nasdaq, and will assume leadership of Nasdaq's Anti-Financial Crime business. The AFC business comprises solutions used by thousands of banks, exchange operators, and other financial institutions for detecting and fighting financial crime through trade and market surveillance, and Verafin's fraud detection and anti-money laundering solutions. King is currently President & CEO of Verafin, which he co-founded in 2003. Roland Chai, currently Nasdaq's Global Chief Risk Officer, will be elevated to Executive Vice President and lead Nasdaq's Market Infrastructure Technology business, which comprises purpose-built products to meet the technology needs of marketplace infrastructure clients. As a result of these changes, John Zecca, Nasdaq's Chief Legal & Regulatory Officer, will assume management of Nasdaq's Group Risk Management team from Roland Chai and will become Chief Legal, Risk & Regulatory Officer.

07:35 EST Arch Biopartners announces Health Canada approved amendment to CATCO protocol - Arch Biopartners announced that Health Canada has approved the amendment to the CATCO protocol to include its lead drug candidate, LSALT Peptide in a new dosing arm of the trial. Health Canada has issued a No Objection Letter for the Clinical Trial Application - Amendment to the CATCO team as part of its approval process. Dosing of LSALT peptide is expected to begin following final local approval and clinical site preparation.

07:33 EST 2seventy Bio appoints Steven Bernstein as CMO - 2seventy Bio announced that Steven Bernstein will join the company effective immediately and assume the role of chief medical officer, or CMO. Also announced, Susan Abu-Absi has been appointed chief technology and manufacturing officer at 2seventy bio. Bernstein has more than 25 years of experience as a treating physician, translational scientist, and pharmaceutical executive. Prior to joining 2seventy, Bernstein served as chief translational officer at Turnstone Biologics. Abu-Absi has over 20 years of experience in biologics and cell and gene therapy process development and manufacturing. She most recently served as our senior VP and head of technical development and operations at 2seventy bio.

07:32 EST Pardes Biosciences presents interim clinical data from PBI-0451 Phase 1 trial - Pardes Biosciences announced that interim clinical data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers has been made available to registered conference attendees at the 29th Conference on Retroviruses and Opportunistic Infections, CROI, 2022. The presentation entitled, "PBI-0451: An Orally Administered 3CL Protease Inhibitor of SARS-CoV-2 for COVID-19," shared details around the nonclinical profile of PBI-0451 as well as interim clinical safety, tolerability, and pharmacokinetics after single- and multiple-ascending doses. In the ongoing first in human Phase I trial, PBI-0451 has been observed to be generally well tolerated over a greater than20-fold single- and greater than14-fold multiple-total daily dose range. All treatment emergent adverse events in the study reported through January 31, 2022 have been assessed as mild in severity and resolved without intervention. In a drug-drug interaction cohort, the pharmacokinetics of PBI-0451 was not substantially affected when co-administered with ritonavir, a potent P-glycoprotein/CYP450 3A inhibitor. In multiple ascending dose cohorts, interim data showed that PBI-0451 twice-daily achieved and maintained PK exposures that the company believes has the potential to provide potent antiviral activity against SARS-CoV-2 and emerging variants. Additional dose cohorts and PK evaluation in this ongoing Phase 1 study continues and will inform dose selection for the upcoming PBI-0451 Phase 2/3 study anticipated to start mid 2022 to evaluate PBI-0451 as a potential treatment of SARS-CoV-2.

07:26 EST New York's MTA orders 60 more battery-electric buses from NFI - NFI Group announced that its subsidiary New Flyer of America has received a new contract from the New York City Transit Authority for 60 battery-electric, zero-emission Xcelsior CHARGE NG forty-foot heavy-duty transit buses. The order is supported by Federal Transit Administration funds and advances NYCT's goal to reduce New York City's carbon footprint through sustainable public transportation. The order is in addition to 15 battery-electric buses previously delivered to NYCT by New Flyer.

07:18 EST Millicom sets out three year operational, financial, strategic targets - Millicom will be holding its 2022 Virtual Investor Day today beginning at 9:00 a.m. ET. Millicom's CEO Mauricio Ramos and the executive team will discuss the company's three-year operational goals, financial targets and strategic plans. Key announcements will include: Targeted organic operating cash flow growth of around 10% per year on average over the next three years. This reflects expected: Mid-single-digit annual organic service revenue growth; and Annual CapEx of around $1.0 billion. Targeted cumulative Equity free cash flow of $800 million to $1.0 billion over the next 3 years. Near-term target to reduce leverage to 2.5x by 2025. With a long-term goal to further reduce leverage to 2.0x. Shareholder remuneration in the form of share buybacks expected to commence in 2023. Buybacks at a pace consistent with the achievement of leverage reduction targets. Expansion of the Company's fixed broadband network by a targeted three million additional home passings in the next 3 years. The vast majority of the new passings will be FTTH, as the Company accelerates its ongoing transition to FTTH. The Company expects to cover 20 million home passings in its territory in the medium term. The Company also aims to add over 1 million customer relationship net additions in the next three years. Plan to create a Tower Company to carve out the Company's portfolio of owned towers. This structural re-organisation, which will include up to 10,000 towers, will be aimed at enhancing shareholder return on the Company's digital infrastructure assets; maximising their business potential; facilitating the attraction of growth capital from new investors; and enhancing strategic optionality around the Company's infrastructure assets. This initiative is expected to be completed in the next 12-18 months. Plan to carve out of TIGO Money. This second structural re-organisation is aimed at enhancing shareholder return on the Company's nascent Fintech asset; maximising their business potential; facilitating the attraction of growth capital and complementary Fintech expertise to TIGO Money; and enhancing strategic optionality for Millicom. TIGO Money has a unique opportunity to increase financial inclusion in TIGO's market while capturing a leading share of an estimated $14 billion total addressable fintech market opportunity. This initiative is also expected to be completed in the next 12-24 months. Setting of ambitious ESG Targets The Company has submitted for validation its near-term Science-Based Targets, in line with a maximum 1.5 degrees C increase and the Paris Climate Agreement. The Company has also become part of Race to Zero, the UN-backed campaign aimed at promoting a healthy, resilient, zero carbon recovery. The Company has set a target of gender parity by 2030. This will include equal gender representation across the entire organisation, as well as in its upper management positions globally. In addition, the Company will continue to train 100% of its employees annually on DE&I; only work with strategic suppliers with DE&I policies & training in place; and continue to promote inclusion of other under-represented groups.

07:15 EST Bitfarms expands management team with three executives - Bitfarms hired three executives for newly created positions to support its growth. Philippe Fortier, Vice President - Special Projects. Serving in various corporate finance and management roles, Fortier played an essential role in a variety of transactional and growth initiatives, both as a principal and advisor to private and listed organizations for over 10 years. Andrea Keen Souza, Vice President - Human Resources. Souza is a senior human resources professional with over two decades of international experience in high growth start-ups, scale-ups, and mergers and acquisitions. Most recently, she was People & Culture Leader at Telus Health Virtual Care. Stephanie Wargo, Vice President - Marketing. Wargo brings 25 years experience and depth of knowledge working for rapidly growing financial services companies. Most recently, Wargo served six years as Vice President, Global Marketing for PrimeRevenue.

07:11 EST Clene Nanomedicine provides clinical program update - Clene along with its wholly owned subsidiary Clene Nanomedicine, provided clinical program updates for its lead nanotherapeutic platform drug candidate: CNM-Au8, as well as its antiviral candidate, CNM-ZnAg. HEALEY-ALS Phase 2/3 Platform Trial on track to report top-line data in the second half of 2022: Enrollment into the HEALEY ALS Platform Trial completed in November 2021. This Phase 2/3 trial is evaluating Clene's drug candidate, CNM-Au8, for the treatment of ALS. Top-line data are expected in the second half of this year. Updated survival data from RESCUE-ALS OLE Phase 2 trial to be presented at upcoming MDA Clinical & Scientific Conference: Updated evidence for a long-term survival benefit with CNM-Au8 treatment from the RESCUE-ALS trial open label extension will be presented at the upcoming MDA Clinical & Scientific Conference March 13-16, 2022 in Nashville, TN. Observed survival in study participants was compared to the estimated median survival derived from the validated ENCALS prediction model with results significantly in favor of CNM-Au8 treatment. Long-Term Expanded Access Program treatment continues: Clene continues to support expanded access programs providing CNM-Au8 treatment at four clinical sites in over 50 participants with ALS. VISIONARY-MS Phase 2 Trial to conclude early due to COVID pandemic-related challenges. Unblinded results expected second half of 2022: The VISIONARY-MS Phase 2 trial is evaluating the efficacy and safety of CNM-Au8 for remyelination and neurorepair in stable relapsing MS patients. Unblinded VISIONARY-MS data are targeted for the second half of 2022, with announcement of the next clinical trial in MS planned thereafter. Clene is currently working with the VISIONARY-MS trial investigators and participants to conclude the trial. REPAIR-MS Phase 2 trial has been Initiated in patients with non-active, progressive MS: Clene has initiated a second MS Cohort to confirm target engagement in the more severe, non-active progressive MS population. CNM-ZnAg Phase 2 COVID trial in Brazil completes full enrollment; top-line data expected mid-2022 : Clene's Phase 2 trial of its antiviral CNM-ZnAg in acutely symptomatic, non-hospitalized COVID-19 patients has achieved full enrollment. Top-line results are expected by mid-year 2022. Clene plans to advance CNM-ZnAg into a registration trial, contingent upon positive Phase 2 results.

07:09 EST Applied Genetic expects cash to fund operations into 2023 - As of December 31, 2021, the Company's cash and cash equivalents totaled $72.8 million. Management believes that these funds will be sufficient to allow the Company to generate data from its ongoing and planned clinical programs and fund currently planned research and discovery programs into calendar year 2023.

07:07 EST nLight acquires process monitoring expert plasmo Industrietechnik, no terms - nLIGH announced that it has acquired the assets of plasmo Industrietechnik GmbH, an Austrian-based provider of automated quality assurance and diagnostic solutions primarily for the welding and additive manufacturing markets. Plasmo's innovative quality assurance solutions empower customers to implement robust, efficient, and cost-optimized production processes. Plasmo's products are driven by proprietary machine vision and analysis software that monitor and help automate a wide range of industrial welding and additive manufacturing processes. Complementing nLIGHT's expanding laser portfolio, the acquisition of the Plasmo assets strengthens nLIGHT's position as a critical enabler of next generation manufacturing solutions in these growth markets. "Plasmo is a technology leader in process monitoring and quality assurance systems for laser-based manufacturing processes," said Jake Bell, general manager for industrial lasers. "Combining lasers with Plasmo's real-time process monitoring solutions provide customers with a significant advantage as they develop, qualify and produce increasingly complex laser-printed or welded parts, particularly for high volume electric vehicle production," said Mr. Bell.

07:06 EST Centene unit to continue serving Louisiana's Medicaid program - Centene announced its subsidiary Louisiana Healthcare Connections was selected by the Louisiana Department of Health to continue administering quality, integrated healthcare services to Medicaid enrollees across the state. The new statewide contract is anticipated to begin July 1. The new Medicaid managed care organization contract is for a term of three years with the option for the state to extend the contract up to two additional years.

07:05 EST Senseonics receives FDA approval for Eversense E3 CGM system - Ascensia Diabetes Care announces that its partner Senseonics Holdings (SENS) has received approval from the FDA for the next-generation Eversense E3 Continuous Glucose Monitoring, or CGM, System. Ascensia plans to make the Eversense E3 sensor, which can be used for up to 6 months, available to patients in the U.S. during the Q2. Developed by Senseonics and brought to people with diabetes by Ascensia, the newly approved Eversense E3 CGM System, which includes a sacrificial boronic acid design modification to enhance sensor survival, offers patients: the longest lasting CGM available, with 6-month sensor wear duration and essentially two sensor insertion and removal procedures per year; exceptional accuracy, with a mean absolute relative difference of 8.5% demonstrated in the PROMISE Study for the duration of sensor wear; a fully implantable fluorescence-based sensor, with a removable smart transmitter* that provides discreet on-body vibratory alerts and transmits data to a mobile app.

07:04 EST Roivant Sciences announces major upcoming milestones - Roivant (ROIV) announced the following major upcoming milestones. Dermavant: Dermavant expects a decision from the FDA on the approval of tapinarof for the treatment of adults with plaque psoriasis in the second quarter of calendar year 2022. Dermavant also expects to report topline data from the Phase 3 clinical trial of tapinarof for the treatment of atopic dermatitis in the first half of calendar year 2023. Immunovant: Immunovant (IMVT) plans to initiate a pivotal trial evaluating batoclimab for the treatment of myasthenia gravis in 1H 2022, with topline results expected in 2024. Immunovant also plans to re-initiate its programs in thyroid eye disease and warm autoimmune hemolytic anemia in 2022, and to announce at least two new indications by August 2022. Immunovant expects to initiate pivotal trials for two of these four indications in 2022, with a total of three pivotal trials initiating in 2022. Aruvant: Aruvant expects to announce ongoing new patient and follow up data through 2022 and to initiate its Phase 3 trial for ARU-1801 for the treatment of sickle cell disease in 2023. Kinevant: Kinevant remains on track to initiate its Phase 2 trial evaluating namilumab for the treatment of sarcoidosis in the first half of calendar year 2022. Hemavant: Hemavant plans to amend its ongoing open-label Phase 1/2 trial evaluating RVT-2001 for the treatment of transfusion-dependent anemia in lower-risk MDS patients in the first half of calendar year 2022, with initial data expected in 2023. Lysovant: Lysovant remains on track to initiate its multiple ascending dose study of LSVT-1701 in patients with complicated Staph aureus bacteremia including infective endocarditis in the first half of calendar year 2022.

07:04 EST Biohaven, Pfizer say rimegepant met co-primary endpoints in acute migraine trial - Biohaven Pharmaceutical (BHVN) and Pfizer (PFE) announced "positive" top-line results from an Asia-Pacific, Phase 3 clinical trial of rimegepant in 1,431 adults for the acute treatment of migraine. Led by BioShin Limited, a subsidiary of Biohaven in China and South Korea, the randomized, regional, multi-center study met the co-primary endpoints evaluating the efficacy and safety of the orally dissolving tablet formulation of rimegepant, an oral calcitonin gene-related peptide receptor antagonist, the companies said. The study met its co-primary endpoints of freedom from pain and freedom from most bothersome migraine-associated symptom including either nausea, phonophobia or photophobia at 2-hours following a single oral dose of rimegepant. In the study, a single oral dose of rimegepant 75 mg provided significant relief of migraine symptoms and return to normal function at 2 hours and delivered sustained efficacy that lasted up to 48 hours for many patients. "Rimegepant showed a favorable safety and tolerability profile among study participants that was consistent with prior clinical trial results in the United States. Detailed data from the study will be presented at future medical meetings to help inform ongoing and future research... This is the fourth positive Phase 3 study of rimegepant for the acute treatment of migraine and the first to be conducted in Asia Pacific," the companies stated. Under the terms of the collaboration agreement between Biohaven and Pfizer, Pfizer has commercialization rights to rimegepant in markets outside of the U.S. Biohaven continues to lead research and development globally and retains the U.S. market. Rimegepant is commercialized as Nurtec(R) ODT in the U.S. and is the only oral CGRP receptor antagonist approved for both the acute and preventive treatment of migraine in adults. An application for the approval of rimegepant is currently under review by the European Medicines Agency with a decision expected in the first half of 2022. Rimegepant is approved for the acute treatment of migraine in Kuwait and the United Arab Emirates, and for the acute and preventive treatment of migraine in Israel.

07:02 EST Bio-Techne announces publication on ExoDx Prostate test - Bio-Techne announced an important publication in World Journal of Urology, entitled Pre-diagnosis urine exosomal RNA, or ExoDx EPI score, is associated with post-prostatectomy pathology outcome. Principal investigator Alexander Kretschmer, urologist from Ludwig Maximilian University of Munich, Germany, and colleagues demonstrated utility of the ExoDx Prostate test, or EPI, to address limitations related to prostate biopsy sampling error, prostate biopsy bias as well as multifocality of the disease, providing a more relevant assessment of low-risk men who could remain on active surveillance. The significance of this study is that in men with an EPI score below the cut-point of 15.6, the ExoDx Prostate test could prevent low-risk men from proceeding to radical prostatectomy. According to the American Cancer Society, active surveillance is often used to monitor prostate cancer closely. Usually this includes a doctor visit with a prostate-specific antigen blood test about every 6 months and a digital rectal exam at least once a year. Prostate biopsies and imaging tests may be done every 1 to 3 years.

06:58 EST Westwater Resources CEO Christopher Jones to retire, Chad Potter to succeed - On February 9, the company announced the retirement of Christopher Jones, President and CEO and a member of the Board, effective February 25. Chad Potter, who is serving as COO, has been elected Westwater's new President and CEO, and appointed to fill the Board vacancy created by Jones' departure, effective February 26. Potter's appointment is the result of a planned succession strategy dating back to 2021. The Board also announced that, effective February 26, Terence Cryan will become the company's Executive Chairman.

06:53 EST BioDelivery Sciences jumps 52% to $5.53 after merger pact with Collegium

06:51 EST Hawaiian Electric reports Q4 EPS 50c, consensus 61c - Reports Q4 revenue $770.27M, consensus $496.9M. "We're proud of how our HEI companies performed in 2021 - financially, for the customers who rely on us, for our communities and for the long-term health of our state," said Scott Seu, HEI president and CEO. "Solid execution on strategic and operational initiatives in 2021 positioned us well to progress our priorities this year."

06:41 EST BitNile increases average daily production to more than one Bitcoin a day - BitNile Holdings published an unaudited update on its Bitcoin production activity. As expected, the most recent delivery of the S19j Pro Antminers have been installed at our Michigan data center thereby increasing BitNile's average daily mining production to more than one Bitcoin per day. BitNile's Bitcoin mining production is currently operating at an estimated annualized run rate of 367.34 Bitcoin based on current market conditions, including a mining difficulty of 26.7 trillion.

06:37 EST Northern Oil and Gas common stock transferred to the NYSE - Northern Oil and Gas announced that the NYSE has approved the transfer of the listing of the Company's common stock from the NYSE American to the NYSE. Effective at the opening of trading on February 17 the common stock of the Company will cease trading on the NYSE American and will commence trading on the NYSE, remaining under the symbol "NOG."

06:34 EST Motus GI Holdings receives 510 clearance from FDA for Pure-Vu EVS System - Motus GI Holdings announced that it has received 510 clearance from the FDA for the Pure-Vu EVS System. The new Pure-Vu EVS System is intended to improve speed of set-up, enhance navigation capabilities in tortuous anatomy, build upon the excellent cleansing capabilities of the Pure-Vu system and enable physicians to rapidly overcome the challenges of poorly prepared colons during a colonoscopy. The Pure-Vu platform facilitates the cleaning of a poorly prepared colon to improve visualization during the colonoscopy procedure. The platform integrates with standard and slim colonoscopes and preserves established procedural workflow by irrigating the colon and evacuating debris to provide a better-quality exam. The commercial launch of the Pure-Vu EVS in the Q1 is anticipated to accelerate speed of adoption in the U.S. and global markets over time. In addition, the advancements made by the Pure-Vu EVS are expected to support future innovation and indication expansion of the Pure-Vu platform.

06:34 EST Collegium Pharmaceutical to acquire BioDelivery Sciences for $5.60 per share - Collegium Pharmaceutical (COLL) and BioDelivery Sciences International (BDSI) announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash. Under the terms of the definitive agreement, Collegium will promptly commence a tender offer to acquire all the outstanding shares of BDSI at the price of $5.60 per share. The offer price of $5.60 represents a 54% premium to BDSI closing share price of $3.64 as of Friday, February 11, and implies a fully diluted equity value of approximately $604M using the treasury stock method. The all-cash consideration will be funded by a combination of Collegium existing cash on hand and a $650M secured financing from funds managed by Pharmakon Advisors, with a four-year term, which will bear an interest rate of Libor+750bps and will be amortized over four years. As part of the transaction, Collegium will repay the existing Collegium term loan from Pharmakon and the existing BDSI term loan from Pharmakon. "Post-closing, we expect Collegium net leverage to be below 3.0x based on estimated fiscal year 2021 pro forma combined EBITDA including run rate synergies. Collegium expects to achieve annual run rate synergies of at least $75 million, based off of BDSI estimated 2021 operating expenses, within twelve months post-closing. Collegium expects this transaction to be highly accretive to earnings in 2022 and 2023. The transaction, which has been unanimously approved by the boards of directors of both companies, is expected to close late in the first quarter 2022, subject to customary closing conditions, including receipt of required regulatory approvals and the tender of a majority of outstanding shares of BDSI's common stock. Following the successful closing of the tender offer, Collegium will acquire any shares of BDSI that are not tendered in the tender offer through a second-step merger at the same consideration as paid in the tender offer."

06:31 EST Collegium Pharmaceutical to acquire BioDelivery Sciences for $5.60 per share

06:05 EST KBR awarded $207M task order - KBR was awarded a $207M task order to conduct multi-disciplined analyses and develop recommendations to enhance the capabilities of the Phased Array Tracking Radar to Intercept on Target, or PATRIOT, missile defense system. KBR was awarded this contract under the Department of Defense Information Analysis Center's, or DoD IAC, multiple-award contract vehicle designed to develop and create new knowledge for the DoD. Under the scope of this task order, KBR will support modeling and simulation efforts for surveillance, guidance, fire control, engagement decision logic, interceptor flyout, seeker, and warhead performance to analyze overall system performance effectively and efficiently. KBR will perform extensive and complex analyses; studies; performance runs; actual live fire, search, track, and flight test missions; hardware-in-the-loop testing; and development and test activities to validate and verify full ground and missile system performance.

05:58 EST Cnooc announces Liza Phase II commences production - Cnooc announced that Liza Phase II had commenced production safely and ahead of schedule. Liza Phase II locates in the Stabroek Block offshore Guyana and produces with 1 FPSO and 30 subsea wellheads. The FPSO is the second production facility in the Block following the one serving Liza Phase I. It was constructed in China and Singapore, and arrived in Guyana in October 2021. It is moored in water depth of about 1,650 meters and will be able to store around 2M barrels of crude oil. Liza Phase II is expected to reach its peak production of approximately 220,000 barrels of crude oil per day within this year.

05:23 EST Kelly Services, Persol Holdings to unwind cross ownership - In other actions taken, Persol Holdings and Kelly have agreed to changes in their relationship in the APAC region. First, Kelly will reduce its ownership interest in PersolKelly Pte., the staffing joint venture established between Kelly and Persol in 2016, from 49% to 2.5%. Persol will acquire 46.5% of the shares held by Kelly through a Persol subsidiary. These changes will have no impact on the operations of PersolKelly, which remains a staffing supplier across the region. PersolKelly will continue to use the brand name, PersolKelly, for a period of time. Second, Kelly and Persol will discontinue their cross-shareholding. Kelly holds 9,106,800 shares of Persol Holdings common stock, and Persol owns 1,576,169 shares of Kelly's Class A common stock and 1,475 shares of its Class B common stock. Kelly will monetize its equity holdings in Persol by selling all its shares in an open market transaction. Kelly will also buy back from Persol its equity position in Kelly. These actions will allow Kelly to realize the appreciation of its equity investment in Persol and enable the company to reinvest in Kelly's specialty growth strategy. Both stock transactions are expected to be completed within two business days.

05:13 EST Mainz Biomed announces ColoAlert partnership with Laboratory Monchengladbach - Mainz Biomed announced a partnership with Labor MVZ Dr. Stein + Kollegen, or Laboratory Monchengladbach. Laboratory Monchengladbach, one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany, will commercialize ColoAlert, Mainz Biomed's detection test for colorectal cancer, ot CRC. With a team of over 500 employees that includes biologists, chemists, doctors and other specialists, Laboratory Monchengladbach services over 2500 physicians, processing over 5M samples in total annually and screening approximately 1000 patients per week specifically for CRC. Under the terms of the partnership, Mainz Biomed will co-brand ColoAlert with Laboratory Monchengladbach, and sell its polymerase chain reaction, or PCR, assay kits for advanced colorectal cancer detection, on an on-demand basis for use by Labor Monchengladbach's network of physicians and their patients. In order to optimize awareness and adoption, Mainz Biomed and Labor Monchengladbach will also collaborate to deliver a comprehensive marketing and education campaign to include direct-to-consumer advertising, cross channel promotion to physician networks, webinars and sales representative training.

05:08 EST Boeing announces annual record for e-commerce parts sales last year - Boeing achieved an annual record for e-commerce parts sales last year with more than $2B in online orders. Fueled by investment in digital tools, Boeing Distribution sold nearly 70,000 parts products through its e-commerce site to commercial and government customers, eclipsing pre-pandemic levels. Commercial orders accounted for $1.5B in sales, reflecting the continued recovery in the airline industry. Boeing Distribution's online revenue last year was 15% higher compared to pre-pandemic levels, while orders were 20% higher.